Clinical Validation of ColonAiQ (a Blood-based Assay Targeting ctDNA Methylation) for Colorectal Cancer Detection

Prior treatment

• Patients who have previously received colorectal cancer surgery, tumor drug therapy, neoadjuvant therapy, or radiotherapy;

Other illness

• Other conditions deemed unsuitable for inclusion by the investigator.

Other

• People who cannot tolerate relevant tests for clinical diagnosis;
• Pregnant women;

• Age ≥18 years old, gender is not limited;
• meet one of the following conditions: 1) Suspected colorectal cancer (CRC); 2) Diagnosed with CRC according to clinical diagnostic criteria; 3) Do not have CRC and have interfering diseases:
  • Confirmed non-CRC digestive tract cases: colorectal polyps, adenomas, and other benign diseases of the digestive system;
  • Confirmed cases of other cancers other than CRC: gastric, esophageal, breast, and lung cancer;
  • diseases where the same gene methylation may be present (non-rheumatoid arthritis, etc.);
• The subject or his/her guardian is able to understand the purpose of the study, demonstrate sufficient adherence to the study protocol, and sign the informed consent.